1 2	PSYCHOTHERAPY MOTIVATION AND CHRONIC PAIN		
3			
4			
5			
6			
7			
י 2			
0	Mativation for nevel alogical treatment predicts for each la autoemas in		
9 10	multimodal interdisciplinary treatment for chronic somatoform pain		
11			
12 13	Julian A. Stewart ^{a, b} , Niklaus Egloff ^a , Roland von Känel ^c , Johannes Grolimund ^{a, b} , Martina Studer ^{a, b} , Martin grosse Holtforth ^{a,b}		
14 15 16 17 18	 ^a Division of Psychosomatic Medicine, Department of General Internal Medicine, Inselspi Bern University Hospital, Bern, Switzerland ^b Department of Psychology, University of Bern, Bern, Switzerland ^c Department of Psychosomatic Medicine, Clinic Barmelweid, Barmelweid, Switzerland 		
19			
20			
21			
22			
23			
24			
25			
26			
27	Corresponding author:		
28	Julian A. Stewart, M.Sc.		
29 30 31	Division of Psychosomatic Medicine, Department of General Internal Medicine, C.L. Lory- Haus, Inselspital, Bern University Hospital, CH-3010 Bern, Switzerland		
ა∠ 33	Fax: $+41 (0)31 632 05 39$		
34	Mail: julian.stewart@insel.ch		
35 36	Financial/nonfinancial disclosures: I and co-authors have no conflicts of interest to report.		

37 Chronic somatoform pain is a frequently occurring disorder that can induce extensive distress, 38 impairment, and disability [1]. Multimodal interdisciplinary treatment represents the treatment of 39 choice [2]; it typically combines psychotherapy, physical therapy and medical interventions [3]. In other words, psychotherapy is a central component within a multimodal interdisciplinary 40 41 treatment setting [3] and it is also considered to be effective for the treatment of chronic pain [4]. 42 Motivation for psychotherapy has been defined as a construct encompassing components of 43 negative illness consequences, psychosocial lay etiology, positive psychotherapeutic treatment 44 expectations and a general openness to psychotherapy [5]. According to the IMMPACT recommendations, core effectiveness outcomes of chronic pain treatment include pain intensity, 45 global rating of improvement, physical functioning and emotional functioning [6]. Means to 46 47 fulfill some of these requirements are numerical rating scales (NRS) to measure pain intensity and depressive symptom scales to assess emotional functioning [7]. Whereas the importance of 48 49 psychotherapy motivation for treatment outcomes has been shown for domains such as somatization syndrome [8], to our knowledge, as yet, no studies have tested prognostic effects of 50 51 psychotherapy motivation on outcomes of multimodal interdisciplinary treatment for chronic 52 somatoform pain.

- 53 The novelty and aim of this study were to investigate the predictive value of initial
- 54 psychotherapy motivation on outcomes of multimodal interdisciplinary treatment of chronic
- somatoform pain. We specifically hypothesized that higher levels of psychotherapy motivation
- so assessed before treatment would be associated with greater reductions in pain intensity (primary
- 57 outcome) and psychological distress, including depressive symptoms (secondary outcomes), all
- 58 independent of age, gender, illness duration and initial levels of outcome measures.
- 59 Between 2011 and 2014, we collected data from 403 consecutive inpatients with chronic
- somatoform pain at the beginning and at the end of a multimodal interdisciplinary treatment
- program at a tertiary psychosomatic university clinic in Switzerland. The inpatient treatment
 program included medical interventions, pharmacotherapy, psychotherapy, relaxation, and
- 63 physical therapy. All participants provided informed consent for the use of their anonymized
- 64 health data for research purposes. The study was conducted in accordance with applicable Swiss
- 65 research legislation. All patients completed a set of standardized self-report assessment tools,
- 66 which were the Questionnaire for the Measurement of Psychotherapy Motivation [5], an 11-point
- 67 numeric rating scale for the mean pain intensity over the last week (NRS, range 0-10), the Beck
- 68 Depression Inventory [7], and the Brief Symptom Inventory to assess general psychological
- distress [9]. In the current study, Cronbach's alpha yielded acceptable to excellent internal
- consistency for the applied scales. Missing data were replaced using multiple imputation. Socio demographic data were complete.
- 72 On average, patients were 48.9 years old (SD = 13.2; range 18-89) and 54.1% (n = 218) were
- 73 women. The average duration of inpatient treatment was 28.8 days (SD = 7.7, range 10–71).
- 74 Whereas psychotherapy motivation at pretreatment correlated significantly with symptoms of

depression (r = 0.36, p < 0.001) and global psychological distress (r = 0.40, p < 0.001), it did not

- 76 with mean pain intensity (r = -0.04, n.s.).
- 77 The primary outcome, mean pain intensity (NRS), decreased significantly from pre- to post-
- treatment (6.6±1.9 vs. 5.6±2.1; p < 0.001; Cohen's d = 0.51). The secondary outcome, mean
- 79 level of depressive symptoms (BDI), decreased significantly from pre- to post-treatment
- 80 (19.3±10.1 vs. 15.0±10.0; p < 0.001; Cohen's d = 0.58). These symptom reductions roughly
- 81 correspond to clinically important improvement (see IMMPACT benchmarks, [6]) of a medium
- 82 effect size. In addition, global psychological distress (BSI) decreased significantly from pre- to
- 83 post-treatment (1.0±0.6 vs. 0.8±0.6; p < 0.001; Cohen's d = 0.45).
- 84 To test the prediction of treatment outcome by initial psychotherapy motivation, we used
- 85 separate hierarchical regression analyses for all outcome variables (Table 1). For all analyses,

- age, gender, illness duration and initial levels of outcome variables were entered as control
- 87 variables in one block. Psychotherapy motivation was entered in the second and final block, and
- uniquely accounted for 2% of the variance in mean pain intensity, 1% in symptoms of depression
- 89 and 2% in global psychological distress at posttreatment, above and beyond effects of the control
- 90 variables. In the final model, greater pretreatment psychotherapy motivation was predictive of 91 lower levels of posttreatment pain intensity ($\beta = -0.14$, t = -2.79, p < 0.01), depressive symptoms
- 91 Tower revers of postreatment pain mensity (p = -0.14, t = -2.79, p < 0.01), depressive symptoms 92 ($\beta = -0.12$, t = -2.37, p < 0.05), and global psychological distress ($\beta = -0.14$, t = -2.78, p < 0.01).
- 93 In sum, our study showed statistically significant reductions in relevant primary (pain intensity)
- 94 and secondary (emotional functioning) outcomes following inpatient multimodal
- 95 interdisciplinary pain treatment. Notably, patients high in initial psychotherapy motivation
- showed greater treatment benefits compared with less motivated patients.
- 97 Psychotherapy motivation appears to be an important predictor of posttreatment pain intensity 98 and emotional wellbeing in multimodal interdisciplinary treatment of chronic somatoform pain 99 in hospitalized patients. The findings from our study may inform interventions targeting the 100 improvement of patients' motivation for psychotherapy to test their potential for enhancing the effectiveness of multimodal pain treatment. Potential targets of such interventions are 101 "psychological-mindedness" regarding illness perception, positive treatment expectations and 102 103 openness for psychological interventions. Initial treatment motivation may also serve as a useful 104 criterion for determining differential treatment selection within an individually tailored treatment 105 program.
- The present study has important limitations. The potential for socially desirable response tendencies of chronic pain patients when completing self-report measurements should be taken into consideration. Since the multimodal treatment program is provided by a number of therapists from different disciplines, the assessment of therapist effects did not seem feasible in this setting. Future research could, for example, employ daily assessments to test more immediate therapist effects that may contribute to the overall outcome. The lack of long-term follow-up data limits interpretation as to whether the observed associations persist beyond
- 113 hospitalization. Thus, future studies could benefit from longitudinal designs to test for
- sustainable effects of psychotherapy motivation on treatment outcomes.

Our study implicates that clinicians may want to pay special attention to chronic somatoform
 pain patients' motivation for psychotherapy. Whether interventions targeting psychotherapy

- 117 motivation may indeed improve treatment outcome in these patients awaits further studies.
- 118
 119
 120
 121
 122
 123
 124
 125
 126
- 127

128	References		
129			
130	1	Grabe HJ, Meyer C, Hapke U, Rumpf HJ, Freyberger HJ, Dilling H, John U:	
131		Somatoform pain disorder in the general population. Psychother Psychosom 2003;72:88–	
132		94.	
133	2	Flor H, Fydrich T, Turk DC: Efficacy of multimodal interdisciplinary pain treatment	
134		centers: a meta-analytic review. Pain 1992;49:221–230.	
135	3	Stanos S, Houle TT: Multidisciplinary and interdisciplinary management of chronic pain.	
136		Phys Med Rehabil Clin N Am 2006;17:435–450.	
137	4	Fava GA, Sonino N: Psychosomatic medicine: Emerging trends and perspectives.	
138		Psychother Psychosom 2000;69:184–197.	
139	5	Schneider W, Basler HD, Beisenherz B: FMP, Fragebogen zur Messung der	
140		Psychotherapiemotivation [Questionnaire for the Measurement of Psychotherapy	
141		Motivation]. Weinheim, Beltz, 1989.	
142	6	Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT,	
143		Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella	
144		D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H,	
145		Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter	
146		L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE,	
147		Stacey BR: Interpreting the clinical importance of treatment outcomes in chronic pain	
148		clinical trials: IMMPACT recommendations. J Pain 2008;9:105–121.	
149	7	Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring	
150		depression. Arch Gen Psychiatry 1961;4:561–571.	
151	8	Timmer B, Bleichhardt G, Rief W: Importance of psychotherapy motivation in patients	
152		with somatization syndrome. Psychother Res 2006;16:348–356.	
153	9	Derogatis LR, Melisaratos N: The brief symptom inventory: an introductory report.	
154		Psychol Med 1983;13:595–605.	